Intercept Pharmaceuticals Inc. (ICPT)’s Positive Liver Cure Overshadows Dismal Second Quarter Results

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) continues to soar in the market after the release of positive clinical data, which showed its drug for a lesser known liver disease is effective; increasing prospects of the same being approved by the FDA. The drug released is called OCA and was found to reverse liver damage by essentially reversing liver scarring or fibrosis, which is most of the time known to cause organ failure or cancer.

Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

“[…] the results are very good, better than we thought. This stock has been up a lot and what happens is I think people like exact sciences. They recognize, you know, what it is a lottery, you have a bunch of this stocks, and one of them is going to pay off, and that’s why the stock market is vibrant because when you have a great orphan drug that does do something special you can have this kind of move,” said CNBC’s Jim Cramer.

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) has already outlined plans to release  full trial results on November 10, 2014 at the American Association study of the Liver Diseases conference in Boston. The pharmaceutical company has also outlined plans to target the drug first on Primary Biliary Cirrhosis, a rare form disease known to cause inflammation that destroys the bile ducts in the liver ultimately leading to scarring.

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)’s stock is already at a high of $295.42 having surged by 24.56% on the release of the positive news awaiting to see the final trading share price as of the close of business. Genfit another French pharmaceutical company has stated that it is developing its own experimental drug, GFT505, which treats NASH.

Genfit and Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) have also stated that plans are underway, to explore partnerships with other drug makers with a view of bringing similar treatment to the market. The release of the positive OCA drug news, looks to have overshadowed dismal quarterly results that the company posted yesterday; having posted an adjusted net loss of $1 a share compared to a net loss of $0.79 reported a year ago.

Disclosure: none

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

10 Covers of Popular Songs that are Better than the Originals

Must See TV: The 9 Most Anticipated Shows of 2015

The 15 Biggest Box Office Bombs of All Time

10 Things The World Can’t Stand About Americans

Picture Perfect: The 6 Smartphones with the Best Cameras

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

The Top 10 Richest Actors in the World

The 10 Best Airline Stocks to Invest In Before They Fly Too High

Burger Kings: The 10 Most Expensive Burgers in the World

The 10 Most Ethnically Diverse Countries in the World

The 10 Most Exclusive Credit Cards in the World

The 10 Most Expensive Cruise Ships in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!